Dermata Therapeutics issues new patent in Japan for DMT410 program

Dermata Therapeutics “announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled ‘Compositions for the treatment of skin conditions,’ further strengthens Dermata’s intellectual property for DMT410 for the treatment of hyperhidrosis and could lead to further protections for additional indications.” CEO Gerry Proehl says: “We believe this patent issuance further validates DMT410’s novel concept to easily deliver botulinum toxin topically instead of requiring patients to receive multiple injections. We are excited about the opportunities the DMT410 program can bring to patients, not only for the treatment of axillary hyperhidrosis as we have seen in our proof-of-concept study, but potentially for palmer and plantar hyperhidrosis which has no currently approved products. We also believe there are opportunities to use DMT410 to treat many aesthetic skin conditions like reducing pore number and size, decreasing sebum production, and reducing fine lines and wrinkles, all while improving the look and quality of facial skin,” continued Mr. Proehl. “We also believe this new patent could aid us in our partnership discussions with a company that has a botulinum toxin to further develop the DMT410 program for multiple indications.”